Federal Contractor Profile
Modernatx, INC.
$10B obligated·6 awards·3 agencies·4 NAICS
Federal Contracts
Showing contracts 1–25 of 25 total. Sorted by action date, most recent first. Excludes $0 modifications.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Sep 21, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00034 | 325414 | DEVELOPMENT OF MRNA VACCINE TO LICENSURE FOR THE PREVENTION OF COVID-19. CLIN 0001 - PRE-AWARD COST, CLIN 0002 - DEVELOPMENT OF MRNA VACCINE TO BLA AND CLIN 0003 - DOMESTIC MANUFACTURING SCALE-OUT | $48M |
| Sep 14, 2023 | Department of Veterans Affairs250-NETWORK CONTRACT OFFICE 10 (36C250) | 36C25023P1813 | 325412 | COVID VACCINES | $12K |
| May 1, 2023 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0100 | 325412 | 100M SARS-COV-2 MRNA-1273 VACCINE DOSES | $508K |
| Aug 16, 2022 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0100 | 325412 | 100M SARS-COV-2 MRNA-1273 VACCINE DOSES | $17M |
| Jun 30, 2022 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0100 | 325412 | 100M SARS-COV-2 MRNA-1273 VACCINE DOSES | $4.8M |
| Apr 14, 2022 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0100 | 325412 | 100M SARS-COV-2 MRNA-1273 VACCINE DOSES | $11M |
| Mar 28, 2022 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0100 | 325412 | 100M SARS-COV-2 MRNA-1273 VACCINE DOSES | $26M |
| Feb 23, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00034 | 325414 | DEVELOPMENT OF MRNA VACCINE TO LICENSURE FOR THE PREVENTION OF COVID-19. CLIN 0001 - PRE-AWARD COST, CLIN 0002 - DEVELOPMENT OF MRNA VACCINE TO BLA AND CLIN 0003 - DOMESTIC MANUFACTURING SCALE-OUT | $308M |
| Jan 21, 2022 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0100 | 325412 | 100M SARS-COV-2 MRNA-1273 VACCINE DOSES | $203K |
| Jun 15, 2021 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0100 | 325412 | 100M SARS-COV-2 MRNA-1273 VACCINE DOSES | $3.3B |
| Jun 10, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00034 | 325414 | DEVELOPMENT OF MRNA VACCINE TO LICENSURE FOR THE PREVENTION OF COVID-19. CLIN 0001 - PRE-AWARD COST, CLIN 0002 - DEVELOPMENT OF MRNA VACCINE TO BLA AND CLIN 0003 - DOMESTIC MANUFACTURING SCALE-OUT | $144M |
| Jun 4, 2021 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0100 | 325412 | 100M SARS-COV-2 MRNA-1273 VACCINE DOSES | $4.0M |
| Mar 16, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00034 | 325414 | DEVELOPMENT OF MRNA VACCINE TO LICENSURE FOR THE PREVENTION OF COVID-19. CLIN 0001 - PRE-AWARD COST, CLIN 0002 - DEVELOPMENT OF MRNA VACCINE TO BLA AND CLIN 0003 - DOMESTIC MANUFACTURING SCALE-OUT | $236M |
| Mar 11, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00034 | 325414 | DEVELOPMENT OF MRNA VACCINE TO LICENSURE FOR THE PREVENTION OF COVID-19. CLIN 0001 - PRE-AWARD COST, CLIN 0002 - DEVELOPMENT OF MRNA VACCINE TO BLA AND CLIN 0003 - DOMESTIC MANUFACTURING SCALE-OUT | $63M |
| Feb 11, 2021 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0100 | 325412 | 100M SARS-COV-2 MRNA-1273 VACCINE DOSES | $1.6B |
| Dec 11, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0100 | 325412 | 100M SARS-COV-2 MRNA-1273 VACCINE DOSES | $2.0B |
| Aug 11, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0100 | 325412 | 100M SARS-COV-2 MRNA-1273 VACCINE DOSES | $1.2B |
| Jul 25, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00034 | 325414 | DEVELOPMENT OF MRNA VACCINE TO LICENSURE FOR THE PREVENTION OF COVID-19. CLIN 0001 - PRE-AWARD COST, CLIN 0002 - DEVELOPMENT OF MRNA VACCINE TO BLA AND CLIN 0003 - DOMESTIC MANUFACTURING SCALE-OUT | $472M |
| Jun 25, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0081 | 325412 | SARS-COV-2 MRNA-1273 VACCINE | $540M |
| May 20, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00034 | 325414 | DEVELOPMENT OF MRNA VACCINE TO LICENSURE FOR THE PREVENTION OF COVID-19. CLIN 0001 - PRE-AWARD COST, CLIN 0002 - DEVELOPMENT OF MRNA VACCINE TO BLA AND CLIN 0003 - DOMESTIC MANUFACTURING SCALE-OUT | $53M |
| Apr 3, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00034 | 325414 | DEVELOPMENT OF MRNA VACCINE TO LICENSURE FOR THE PREVENTION OF COVID-19. CLIN 0001 - PRE-AWARD COST, CLIN 0002 - DEVELOPMENT OF MRNA VACCINE TO BLA AND CLIN 0003 - DOMESTIC MANUFACTURING SCALE-OUT | $430M |
| Apr 19, 2018 | Department of DefenseNAVAL MEDICAL RESEARCH CENTER | N3239818P0224 | 541714 | IGF::OT::IGF MRNA PRODUCTION (4MG) | $83K |
| Mar 20, 2017 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600029C | 541711 | MODERNA THERAPEUTICS, INC:ADVANCE THE DEVELOPMENT OF AN MRNA VACCINE FOR THE PREVENTION OF ZIKA VIRUS:: IGF::OT::IGF | $65M |
| Sep 16, 2016 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600029C | 541711 | MODERNA THERAPEUTICS, INC:ADVANCE THE DEVELOPMENT OF AN MRNA VACCINE FOR THE PREVENTION OF ZIKA VIRUS:: IGF::OT::IGF | $44M |
| Sep 1, 2016 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600029C | 541711 | MODERNA THERAPEUTICS, INC:ADVANCE THE DEVELOPMENT OF AN MRNA VACCINE FOR THE PREVENTION OF ZIKA VIRUS:: IGF::OT::IGF | $8.2M |
Get Alerted Before Modernatx, INC.'s Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start Free